Benzinga | Jan 21, 2022 06:26AM EST

Needham Maintains Buy on Conmed, Lowers Price Target to $150

Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $158 to $150.